TECHNOLOGY FOR SOCIAL IMPACT
Improve the quality of life of the people
We are an interdisciplinary group that works to make technologies that provide a better quality of life to the people. Our motivation is people, so we work hard to improve day by day with you. Get to know us.
An unquestionable objective
We have very clear objectives.
We only understand technological development if it has a social impact, which is why we spend part of our income to R+D projects and part of our profits to social action.
mjn-neuro has a positive impact on our society, as we explain in our Theory of Social Change. Also, we will periodically measure our impact and publish the results obtained. Discover the importance of social change in MJN.
5
of our profit will be dedicated to promote social projects
10
of our sales will go to research and innovation
Awards and recognitions
Vodafone Foundation’s Award for Innovation in the ICT Social Solution Category.
Finalist and accesit
of Emprendedor XXI de CaixaBank Finalist and accesit 2018.
International Award for Social Innovation e-health category Mapfre Foundation.
Caser Prize: 1st Prize Dependency and Society Category R&D
1st prize d_Lab international award organized by MWC 2017.
Among the 3 best startups in the health sector of Catalonia Premis Acció 2017.
Award best wearbale technology fair IDTechEx Berlin 2017.
Finalist and accesit 2018.
Project awarded by Netmentora Catalunya.
1st prize Las Vegas
Funding Summit.
Top Catalan IOT Start-up.
5th prize in the M2D2 medical device competition, UMASS University, Boston
Hello Tomorrow: Deep Tech PIONEER Recognition, Paris
WSA: Among the 5 best projects worldwide about Digital Health and SDG
2nd International Top IA Health Project Award, Düsseldorf
EiB finalist, recognition as one of the 15 projects with the best social impact in Europe, Dublin
Global Champion WSA. World’s Best Digital Health Project by World Summit Awards, Vienna
This international certificate recognizes that mjn-neuro is compliant with all requirements specified to sell and provide medical products and services.
This certificate indicates that the solution developed by mjn-neuro to evaluate the risk of epilepsy seizures is a medical device that complies with directive 93/42/EEC.
Our commitment to excellence
Everything we do in mjn-neuro is compliant with the highest quality standards.
mjn-neuro has the ISO 13485:2016 quality certificate, the Manufacturer’s License from the Spanish Agency of Medicines and Health Products and the CE certificate as a class IIa medical device. You can also read our quality policy here.
Our team
Get to know the mjn-neuro team
You already know us and mjn-neuro is committed both to innovation in technology and to the social impact of each…
We interviewed Clara Gelabert, our CFO. She has been part of the mjn-neuro team for more than two years...
Our collaborators
We are not alone helping people with epilepsy
Grant programs
EIT Health (European Institute of Innovation and Technology) and the European Union, Start-up Amplifier Instrument. Grant 220445
PROJECT: IMPROVING QUALITY OF LIFE FOR PEOPLE WITH EPILEPSY IN EUROPE
CONSORTIUM: MJN-NEURO (SPAIN), OXFORD UNIVERSITY HOSPITAL NHS FOUNDATION TRUST (UNITED KINGDOM), DIAKONIE KORK (GERMANY), CLÍNICA UNIVERSIDAD DE NAVARRA (SPAIN), SYNAPTIA (SPAIN), DKV SALUD (SPAIN), MEDTRONIC ( SPAIN), MEDICAL VALLEY (GERMANY), IESE BUSINESS SCHOOL (SPAIN), BIOCAT (SPAIN) AND DKV INTEGRALIA FOUNDATION (SPAIN).
With this European grant of 2.76 million euros, mjn-neuro intends to enter the European market with its mjn-SERAS device, the world’s first device capable of providing early warning of an epileptic seizure.
Proyecto CPP2021-008311
VISOR EEG (dispositiVo regIStro hOlter seRas EEG)
The main objective of the project is the creation of an out-of-hospital Holter EEG recording system using portable, discreet and non-invasive devices, so that the patient can carry out daily life activities at the same time as their brain electrical activity is recorded, in an easier and more comfortable way for the patient. In addition, this system will provide the analysis of quantitative and qualitative characteristics of the EEG signal using artificial intelligence algorithms.
Proyecto ICEXNP_202102281388
Estrategia internacional para mjn-SERAS
ICEXNEXT Program
Project for the development of an international strategy in the area of business, marketing and general management, for the product mjn-SERAS for epilepsy. Considering market identification, product niche, competition and marketing channels.
Carried out in collaboration with consultant Wilhelm Lappe.
Project subsidized by the EUROPEAN REGIONAL DEVELOPMENT FUND (ERDF). A way of doing Europe.
Program "Cupons a la innovació 2020 ACCIÓ" Generalitat de Catalunya
Alzhemeir's detection device prototype
The project subsidized by Acció aims to develop a functional prototype capable of recording the brain activity of any person in a fast, simple and portable way in a standardized way, without any type of customization and whose design allows batches to achieve economies of scale.
File: ACE008/20/000316
"Misiones CDTI" program
Project: Dreamer: EARLY DETECTION OF ALZHEIMER'S
Project for the early detection of signs that allow the diagnosis of Alzheimer’s disease in the preclinical phase, through cognitive markers and electroencephalographic records, with the development of a portable and
non-invasive device and the use of artificial intelligence.
The project has a duration of three years (01/10/2020 – 31/12/2022) and is carried out entirely in Catalonia by the participants ELAUSA ELECTRONICA I AUTOMATISMES S.L., INSTITUTO MEDICO PRIVADO, S.L.P., MJN NEUROSERVEIS S.L. y WEIRD KIN S.L.
It has a budget of €2,095,799 and a grant of €1,444,491.15.
Document: EXP 00135659 / MIP_20201050
DREAMER is a project subsidised by the CDTI with the support of the Ministry of Science and Innovation.
Subsidised by CDTI
Retos Colaboración MJN-eXiT (Universitat de Girona)
Project: mjn-SERAS, Device for the evaluation of the risk of epileptic seizures
The main objective of the project is to improve the quality of life of patients with epilepsy through the development of a solution that will be capable of detecting and alerting epilepsy seizures suffered by this type of patient and thereby avoiding accidents resulting from these situations.
To achieve this objective, the project collaborates with the company mjn-neuro, which will take the lead into this initiative. The project will also count on the UDG eXiT Research Group who has a long experience in creating predictive methods from biomedical data.
Project funded by FEDER / Ministry of Science, Innovation, and Universities – State Research Agency / Project (RTC-2017-6701-1).
The main objective of this call is to promote technological development, innovation and quality research.
Horizon 2020, SME Instruments 2018-2020. Grant 849781
Project: Seizure Risk Assessment for epilepsy
See more
